CCM
MACK

Cadence Capital Management’s Merrimack Pharmaceuticals, Inc. MACK Stock Holding History

Cadence Capital Management’s Portfolio MACK Stock Details MACK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-41,773
Closed -$4.06M – 688
2015
Q2 		$4.06M Buy
41,773
+1,893
+5% +$180K 0.23% 122
2015
Q1 		$3.73M Sell
39,880
-4,454
-10% -$379K 0.23% 118
2014
Q4 		$3.94M Buy
44,334
+19,815
+81% +$1.44M 0.23% 129
2014
Q3 		$1.69M Buy
+24,519
New +$1.31M 0.09% 269

Other funds holding MACK

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
TCIM
TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
LIM
Lagoda Investment Management New York $162M AUM 49.7% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
TA
Teachers Advisors New York $81.7B AUM 13.62% 1-Year Est. Return

Cadence Capital Management's MACK Position: Q3 2015 in Review

Cadence Capital Management sold out of Merrimack Pharmaceuticals, Inc. (MACK) in Q3 2015, closing a stake of 41,773 shares — an estimated $4.06M sold.

Cadence Capital Management first reported a position in MACK in Q3 2014 and held it in 4 quarters. The position peaked at $4.06M in Q2 2015. 135 funds tracked by Wall St. Rank hold MACK as of Q3 2015.

  • Cadence Capital Management reported no remaining Merrimack Pharmaceuticals, Inc. position as of Q3 2015 after selling out during the quarter.
  • Cadence Capital Management sold 41,773 Merrimack Pharmaceuticals, Inc. shares in Q3 2015, an estimated $4.06M.
  • Cadence Capital Management first reported a position in Merrimack Pharmaceuticals, Inc. in Q3 2014 and held it in 4 quarters.
  • Cadence Capital Management's Merrimack Pharmaceuticals, Inc. position peaked at $4.06M in Q2 2015.
  • 135 funds tracked by Wall St. Rank held Merrimack Pharmaceuticals, Inc. as of Q3 2015.

Based on Cadence Capital Management's 13F filing for Q3 2015, filed 12 Nov 2015.